Status:
COMPLETED
Dose-finding Study for the Ultralow-dose Levonorgestrel Intrauterine Contraceptive System (LCS)
Lead Sponsor:
Bayer
Conditions:
Contraception
Eligibility:
FEMALE
21-40 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to investigate if drug doses lower than the one released from Mirena® would be as effective for contraception as Mirena®. Subjects participating in the study will be rando...
Detailed Description
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany. Bayer Schering Pharma AG, Germany is the sponsor of the trial...
Eligibility Criteria
Inclusion
- Women with or without children and good general health and in need of contraception.
- Regular menstrual cycle without hormonal contraceptives.
Exclusion
- Pregnant or lactating.
- Last delivery or abortion less than 12 weeks ago.
- Previous pregnancies outside the womb.
- Previous pelvic infections.
- Abnormal bleeding.
- Abnormal uterine cavity.
- Climacteric signs.
- Genital cancer.
- Liver diseases.
- Alcoholism or drug abuse.
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2008
Estimated Enrollment :
742 Patients enrolled
Trial Details
Trial ID
NCT00185380
Start Date
April 1 2005
End Date
December 1 2008
Last Update
June 10 2015
Active Locations (35)
Enter a location and click search to find clinical trials sorted by distance.
1
Espoo, Finland, 02100
2
Helsinki, Finland, 00100
3
Joensuu, Finland, 80100
4
Jyväskylä, Finland, 40620